Illumina, Inc. $ILMN Stock Sold by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al lessened its holdings in Illumina, Inc. (NASDAQ:ILMN) by 43.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 165,811 shares of the life sciences company’s stock after selling 129,900 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Illumina were worth $45,379,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Soltis Investment Advisors LLC boosted its position in Illumina by 29.6% during the 3rd quarter. Soltis Investment Advisors LLC now owns 1,994 shares of the life sciences company’s stock worth $546,000 after acquiring an additional 455 shares during the period. Choreo LLC increased its holdings in shares of Illumina by 8.5% in the 3rd quarter. Choreo LLC now owns 5,538 shares of the life sciences company’s stock valued at $1,516,000 after purchasing an additional 435 shares during the period. Hanseatic Management Services Inc. acquired a new position in shares of Illumina in the 3rd quarter valued at about $1,603,000. VestGen Advisors LLC purchased a new stake in shares of Illumina in the third quarter worth approximately $392,000. Finally, Laurel Wealth Advisors LLC purchased a new stake in shares of Illumina in the third quarter worth approximately $55,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Adjusted earnings exceeded expectations. Illumina reported third-quarter adjusted EPS of $1.44, above the $1.36 consensus estimate, while revenue increased 4.2% year over year to approximately $1.13 billion. Illumina Reports Financial Results for Third Quarter
• Positive Sentiment: Full-year guidance was raised. Management increased its 2026 outlook, with revenue guidance of roughly $4.65 billion at the midpoint, supported by clinical sequencing demand and continued adoption of the NovaSeq X platform. ILMN Q3 Earnings Call Highlights
• Positive Sentiment: Long-term industry demand remains favorable. Recent market reports point to strong growth in clinical genomics, sequencing-as-a-service, population screening, and AI-enabled genomic analysis—markets in which Illumina is a major participant. These reports are industry forecasts rather than new company contracts or financial commitments.
• Neutral Sentiment: Analyst sentiment became more cautious. JPMorgan reduced its price target from $320 to $300, while Robert W. Baird maintained a Hold rating. The target cut suggests less near-term upside following Illumina’s substantial prior rally. JPMorgan Adjusts Price Target
• Negative Sentiment: Revenue performance disappointed investors. Although earnings surpassed estimates, quarterly revenue was below consensus in several reports, highlighting softer demand than expected and limiting the impact of the profit beat.
• Negative Sentiment: China exposure, tariffs, and business mix remain concerns. Investors are worried about China-related revenue challenges, tariff uncertainty, research-market weakness, and pricing pressure. A broader pullback in AI-linked technology stocks also hurt sentiment toward Illumina. Illumina Shares Tumble on China Woes

Illumina Trading Down 18.6%

NASDAQ:ILMN opened at $235.99 on Friday. The company’s 50 day moving average is $249.30 and its 200-day moving average is $176.18. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 12 month low of $106.12 and a 12 month high of $309.35. The firm has a market cap of $35.63 billion, a price-to-earnings ratio of 40.62, a P/E/G ratio of 4.11 and a beta of 1.41.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.36 by $0.26. Illumina had a net margin of 19.72% and a return on equity of 29.41%. The company had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.15 billion. During the same period in the prior year, the company earned $1.34 earnings per share. The business’s quarterly revenue was up 4.2% compared to the same quarter last year. Equities analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on ILMN. Stephens downgraded shares of Illumina from an “overweight” rating to an “equal weight” rating and set a $275.00 price objective on the stock. in a research report on Friday, October 23rd. Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Sunday, October 11th. Barclays lifted their target price on shares of Illumina from $160.00 to $200.00 and gave the company an “underweight” rating in a research note on Wednesday, October 7th. Piper Sandler boosted their price target on shares of Illumina from $225.00 to $305.00 and gave the company an “overweight” rating in a report on Monday, September 28th. Finally, Guggenheim lifted their price target on Illumina from $226.00 to $305.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Nine investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, Illumina presently has a consensus rating of “Hold” and an average target price of $238.53.

Insider Buying and Selling

In other Illumina news, Director Keith Meister sold 457,858 shares of the firm’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the sale, the director directly owned 2,372,694 shares in the company, valued at $474,776,069.40. This trade represents a 16.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In the last ninety days, insiders have sold 2,061,235 shares of company stock worth $436,356,102. 2.90% of the stock is owned by corporate insiders.

About Illumina

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.